Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.

Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH.

Br J Pharmacol. 2014 Dec;171(23):5330-44. doi: 10.1111/bph.12846.

2.

Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.

Conley BA, Ramsland TS, Sentz DL, Wu S, Rosen DM, Wollman M, Eiseman JL.

Cancer Chemother Pharmacol. 1999;43(3):183-97.

PMID:
9923548
3.

Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

Int J Oncol. 2008 Nov;33(5):1081-9.

PMID:
18949372
4.

Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells.

Veal GJ, Errington J, Redfern CP, Pearson AD, Boddy AV.

Biochem Pharmacol. 2002 Jan 15;63(2):207-15.

PMID:
11841795
5.

Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.

Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM.

Clin Cancer Res. 1996 Jun;2(6):1077-82.

6.

Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.

Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Påhlman S, Guzhova I, Larsson LG.

Mol Cancer Ther. 2007 Oct;6(10):2634-41.

7.

The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.

Ponthan F, Borgström P, Hassan M, Wassberg E, Redfern CP, Kogner P.

Med Pediatr Oncol. 2001 Jan;36(1):127-31.

PMID:
11464864
8.
9.

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.

Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R.

Clin Cancer Res. 2005 May 1;11(9):3535-42.

10.
11.

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.

Mol Cancer Ther. 2007 Jan;6(1):70-81.

14.

Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma.

Hara I, Taguchi I, Miyake H, Hara S, Gotoh A, Kamidono S.

Int J Oncol. 2001 Nov;19(5):959-62.

PMID:
11604994
15.

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation.

Khan AA, Villablanca JG, Reynolds CP, Avramis VI.

Cancer Chemother Pharmacol. 1996;39(1-2):34-41.

PMID:
8995497
16.

Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells.

Han G, Chang B, Connor MJ, Sidell N.

Differentiation. 1995 Jul;59(1):61-9.

PMID:
7589896
17.

Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.

Wadler S, Schwartz EL, Anderson P, Runowicz CD, Chuang L, Del Priore G, Hochster H, Goldberg G, Fields A, Loewen G, Haynes H.

Cancer J Sci Am. 1999 May-Jun;5(3):165-70.

PMID:
10367173
18.

13-cis retinoic acid and isomerisation in paediatric oncology--is changing shape the key to success?

Armstrong JL, Redfern CP, Veal GJ.

Biochem Pharmacol. 2005 May 1;69(9):1299-306. Review.

PMID:
15826600
19.
20.

Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men.

Weber C, Dumont E.

J Clin Pharmacol. 1997 Jul;37(7):566-74.

PMID:
9243349

Supplemental Content

Support Center